[ad_1]
Anschober sees the approval of the corona vaccine as the turning point in the fight against the pandemic.
© WHAT / GEORG HOCHMUTH
In view of the forthcoming approval of the Biontech / Pfizer corona vaccine, Health Minister Rudolf Anschober spoke on Monday of a “radical change in the fight against the pandemic.”
After the European Medicines Agency (EMA) gave the green light on Monday to the approval of the corona vaccine from Mainz-based company Biontech and its US partner Pfizer, Health Minister Rudolf Anschober (Greens) announced in a broadcast of a “twist in the fight against the pandemic” discussed.
Two doses are needed for protection from vaccination
The first doses of vaccine can be expected in Austria soon. With this, “then we started vaccinating in homes for the elderly and the elderly,” Anschober said.
In total, Bionzech will deliver one million cans in the first quarter, of which around 230,000 will be in the first four weeks. “After that, we continue to have market approval from Moderna in early January, and then a delivery of this vaccine of 200,000 doses in the first quarter. And then a market approval of the vaccine from AstraZeneca in February. Minister of Health Two doses are required for vaccination protection.
EMA gave the green light to the Biontech and Pfizer corona vaccine
The EMA Committee for Medicinal Products for Human Use (CHMP) has completed its rigorous evaluation of the Comirnaty vaccine and concluded that there is now sufficient robust data on the quality, safety and efficacy of the vaccine to obtain a conditional marketing authorization. formal. recommend. This will provide a robust and controlled framework to support vaccination campaigns across the EU and protect EU citizens.
The decision is based on a clinical study involving about 44,000 people. Half received the vaccine and half received placebo. People didn’t know if they were getting the vaccine or the sham injection.
Minor side effects: safety will continue to be monitored
Efficacy has been estimated in more than 36,000 people 16 years of age and older (including people older than 75 years) who had no evidence of prior infection. The study showed a 95 percent reduction in the number of symptomatic Covid-19 cases among people who received the vaccine (eight of 18,198 cases had Covid-19 symptoms) compared to people who received a sham injection (162 of 18,325 cases showed symptoms of Covid-19). This means that the vaccine was 95 percent effective in the clinical study.
The vaccine is given as two injections in the arm at least 21 days apart. The most common side effects with Comirnaty were generally mild or moderate and improved within days after vaccination. These included pain and swelling at the injection site, fatigue, headache, muscle and joint pain, chills, and fever. The safety and efficacy of the vaccine will continue to be monitored as it is used in the Member States through the EU pharmacovigilance system and further studies by the company and the European authorities.
[ad_2]
